Business Wire

Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting

Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting - New data ...
Business Wire

Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia

NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced positive topline results ...
Becker's ASC

The 20 most common ASC procedures

MedPac in its March 2020 report to Congress made a series of recommendations on ASCs and documented several statistics on the industry. Injection procedure for sacroiliac joint, anesthetic: 1.4 ...
Labroots

Study Explores Patient Preferences for Cervical Screening Procedures

Experts estimate that over 13,000 new cervical cancer diagnoses occurred in the United States in 2025, accompanied by over 4,000 cervical cancer-related deaths. Five-year survival for patients ...